ANAB.NASDAQAnaptysbio, INC

Form 4: AnaptysBio Director Magda Marquet Acquires 6,030 Shares Through RSU Conversion

Sentiment:

Insider Transaction Report


AnaptysBio, Inc. Director Magda Marquet has increased her direct beneficial ownership by 6,030 shares of common stock following the conversion of restricted stock units.

Summary

  • Magda Marquet, a Director of AnaptysBio, Inc. (ANAB), acquired 6,030 shares of the company's common stock.
  • The acquisition occurred on June 15, 2025, and was a result of the exercise (conversion) of Restricted Stock Units (RSUs).
  • Each RSU represents a contingent right to receive one share of common stock upon settlement for no consideration.
  • Following this transaction, Ms. Marquet's direct beneficial ownership of AnaptysBio common stock increased to 9,930 shares.
  • The RSUs vested 100% on the date of the Issuer's 2025 annual meeting of shareholders, contingent on Ms. Marquet's continued service to the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates a director increasing their direct ownership in the company, which can be viewed as a sign of confidence. However, it's a pre-scheduled RSU conversion, not an open market purchase, so the positive signal is moderate.

Positives

  • The acquisition of shares by a director, Magda Marquet, through the conversion of Restricted Stock Units (RSUs) increases her direct beneficial ownership in AnaptysBio, Inc.
  • Increased insider ownership can signal confidence in the company's future prospects and better align the director's interests with those of shareholders.

Future Outlook

The vesting of the Restricted Stock Units (RSUs) was contingent on the Reporting Person's continued service to the Issuer until the date of the Issuer's 2025 annual meeting of shareholders, indicating an expectation of continued service.

Industry Context

This Form 4 filing reports a routine insider transaction related to equity compensation, which is common across all industries for directors and executives. It does not provide broader industry trends or competitive insights.

Related Party Transactions

  • The transaction involves the conversion of Restricted Stock Units (RSUs) granted to a director as part of their compensation, which is a common form of related party transaction.

Stakeholder Impact

  • Shareholders: Increased direct ownership by a director may align their interests more closely with shareholders, potentially signaling confidence in the company's long-term performance.
  • Employees: The RSU vesting mechanism is a standard compensation practice, which can be seen as a positive for employee retention and motivation, particularly for key personnel.

Key Dates

DateDescription
06/15/2025Date of transaction where 6,030 shares of Common Stock were acquired through RSU conversion.
06/17/2025Date the Form 4 was signed by Eric Loumeau, Attorney-in-Fact for Magda Marquet.
2025 annual meeting of shareholdersDate when the Restricted Stock Units (RSUs) vested 100%, subject to the Reporting Person's provision of service.

Keywords

ANAPTYSBIO, ANAB, Form 4, Insider Transaction, Stock Acquisition, Director, Restricted Stock Unit, RSU Conversion, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.